ADH-503
new
featured

MedKoo is just lunching a new version of website. The shopping cart is not working properly. We will fix it ASAP.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 408039

CAS#: 2055362-74-6

Description: ADH-503 is a potent agonist of the integrin CD11b to mitigate myeloid cell immunosuppression. The partial activation of CD11b by ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhanced dendritic cell responses. These actions, in turn, improve antitumor T cell immunity and render checkpoint inhibitors effective in previously unresponsive PDAC models.


Price and Availability

Size Price Shipping out time Quantity
50mg USD 450 2 Weeks
100mg USD 850 2 Weeks
200mg USD 1350 2 Weeks
500mg USD 2250 2 Weeks
1g USD 3450 2 Weeks
2g USD 5650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-02-27. Prices are subject to change without notice.

ADH-503, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 408039
Name: ADH-503
CAS#: 2055362-74-6
Chemical Formula: C28H32N2O4S2
Exact Mass:
Molecular Weight: 524.694
Elemental Analysis: C, 64.10; H, 6.15; N, 5.34; O, 12.20; S, 12.22


Synonym: ADH-503; ADH 503; ADH503;

IUPAC/Chemical Name: 2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-methyl-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate

InChi Key: HIJWAHUTJVGURK-GNWMQEPYSA-M

InChi Code: InChI=1S/C23H19NO3S2.C5H14NO/c1-15-21(29-23(28)24(15)14-16-5-3-2-4-6-16)13-19-11-12-20(27-19)17-7-9-18(10-8-17)22(25)26;1-6(2,3)4-5-7/h2-13,15H,14H2,1H3,(H,25,26);7H,4-5H2,1-3H3/q;+1/p-1/b21-13-;

SMILES Code: C(=O)([O-])C1C=CC(C2=CC=C(/C=C3\SC(=S)N(CC4=CC=CC=C4)C\3C)O2)=CC=1.[N+](CCO)(C)(C)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


Additional Information

Although checkpoint immunotherapies have revolutionized the treatment of cancer, not all tumor types have seen substantial benefit. Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in which very limited responses to immunotherapy have been observed. Extensive immunosuppressive myeloid cell infiltration in PDAC tissues has been postulated as a major mechanism of resistance to immunotherapy. Strategies concomitantly targeting monocyte or granulocyte trafficking or macrophage survival, in combination with checkpoint immunotherapies, have shown promise in preclinical studies, and these studies have transitioned into ongoing clinical trials for the treatment of pancreatic and other cancer types.


References

1. RZ Panni et al. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Sci Transl Med. 2019 Jul 3;11(499).

2. I Dickson. CD11b agonism overcomes PDAC immunotherapy resistance. Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):514.

3. D Maiguel et al. Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci Signal. 2011 Sep 6;4(189):ra57.